About VaxEquity
VaxEquity is a UK biotechnology company developing next generation self-amplifying RNA and mRNA therapeutics and vaccines. Our proprietary RNA platform is designed to modulate the innate immune response to enable higher and longer protein expression allowing lower doses and expanding the potential of RNA for therapeutics as well as vaccines.
VaxEquity was founded in 2020 by Imperial College London’s Professor Robin Shattock, and specialist life sciences investor Morningside, and is led by a world class team who are RNA pioneers. The Company is based in Cambridge, UK, and is collaborating with AstraZeneca to progress its platform across multiple disease areas.
To learn more about VaxEquity please visit www.vaxequity.com and follow our LinkedIn.